Literature DB >> 21425445

Four novel ELANE mutations in patients with congenital neutropenia.

Maria Kurnikova1, Michael Maschan, Evgeniya Dinova, Irina Shagina, Natalia Finogenova, Elena Mamedova, Tatyana Polovtseva, Dmitry Shagin, Anna Shcherbina.   

Abstract

Congenital neutropenia is a heterogeneous bone marrow failure syndrome characterized by a maturation arrest of myelopoesis at the promyelocyte/myelocyte stage. Cyclic neutropenia (CyN) and severe congenital neutropenia (SCN) are two main forms of congenital neutropenia. Genetic analysis has shown that heterozygous mutations in the ELANE gene encoding the neutrophil elastase are the major cause of these disorders. We investigated the prevalence of ELANE mutations in a group of 16 patients from 14 families with congenital neutropenia. Five patients had typical manifestations of CyN, and 11 patients had SCN. Seven different heterozygous ELANE mutations were found, including four novel mutations.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425445     DOI: 10.1002/pbc.23104

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

1.  Novel ELANE Gene Mutation in a Newborn with Severe Congenital Neutropenia: Case Report and Literature Review.

Authors:  Yue Jia; Changjun Yue; Kathryn Bradford; Xin Qing; Eduard H Panosyan; Moran Gotesman
Journal:  J Pediatr Genet       Date:  2019-11-18

Review 2.  Neutrophil Elastase Inhibitors and Chronic Kidney Disease.

Authors:  Elsa Bronze-da-Rocha; Alice Santos-Silva
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

3.  Extended Cleavage Specificity of Human Neutrophil Elastase, Human Proteinase 3, and Their Distant Ortholog Clawed Frog PR3-Three Elastases With Similar Primary but Different Extended Specificities and Stability.

Authors:  Zhirong Fu; Michael Thorpe; Srinivas Akula; Gurdeep Chahal; Lars T Hellman
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.